Brian L Heiss

6PUBLICATIONS
35CO-AUTHORS
Medical biotechnology not elsewhere classifiedMolecular targetsPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 18, 2025
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.

Brian L Heiss, Elaine Chang, Hee-Koung Joeng

|Sep 09, 2024
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma.

Jaleh Fallah, Brian L Heiss, Hee-Koung Joeng

|Aug 29, 2024
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations.

Jaleh Fallah, Jianjin Xu, Hee-Koung Joeng

|Mar 14, 2024
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.

Jaleh Fallah, Jianjin Xu, Chana Weinstock

|Mar 07, 2024
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.

Brian L Heiss, Elaine Chang, Xin Gao

|Aug 04, 2020
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19.

Garth W Strohbehn, Brian L Heiss, Sherin J Rouhani

Pageof 1

Frequent Collaborators

5 joint publications

Richard Pazdur

5 joint publications

Laleh Amiri-Kordestani

4 joint publications

Elaine Chang

4 joint publications

Xin Gao